The Effects of Raloxifene on Bone Turnover Markers and Bone Mineral Density in Women on Maintenance Hemodialysis

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2010 Nov 12

PMID 21069410

Citations 6

Authors

Osamu Saito

Takako Saito

Shinji Asakura

Taro Sugase

Chiharu Ito

Yasuhiro Ando

Shigeaki Muto

Eiji Kusano

Affiliations

Soon will be listed here.

Abstract

Background: Bone disease is caused not only by increased bone turnover accompanying secondary hyperparathyroidism but also by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis in hemodialysis patients. In this study, we investigated the effects of raloxifene on bone turnover markers and bone mineral density (BMD) in female hemodialysis patients to determine involvement of estrogen deficiency in bone disease.

Methods: The subjects were 47 female patients on maintenance hemodialysis. Raloxifene hydrochloride (60 mg) was administered to 21 patients for 1 year, and these patients were compared with a control group of 26 patients. Serum levels of N-terminal cross-linking telopeptide of type I collagen (NTx), bone alkaline phosphatase, and intact parathyroid hormone were measured, and BMD was determined by quantitative heel ultrasound as the speed of sound (SOS) in the calcaneus over this period.

Results: NTx decreased after treatment with raloxifene for 1 year, but significantly increased in the control group. SOS increased after treatment with raloxifene for 1 year, but significantly decreased in the control group. Treatment with raloxifene resulted in a significant decrease of NTx and a significant increase of SOS in subgroups of patients aged <60 and ≥ 60 years.

Conclusions: Treatment with raloxifene can suppress a rise in NTx and increase bone mineral density in patients around the time of menopause and in postmenopausal patients of advanced age. A reduction in bone mineral density caused by estrogen deficiency may be involved in the development of bone disease in female hemodialysis patients.

Citing Articles

Estrogen and estrogen receptors in kidney diseases.

Ma H, Chen S, Du Y Ren Fail. 2021; 43(1):619-642.

PMID: 33784950 PMC: 8018493. DOI: 10.1080/0886022X.2021.1901739.

Sex hormones impact vascular calcification and fracture in dialysis patients.

An W Kidney Res Clin Pract. 2020; 39(3):236-238.

PMID: 32958722 PMC: 7530354. DOI: 10.23876/j.krcp.20.129.

Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study.

Lin Y, Lee T, Chen C, Lin S, Hwang S, Lin M PLoS One. 2020; 15(9):e0238248.

PMID: 32877436 PMC: 7467303. DOI: 10.1371/journal.pone.0238248.

Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis.

Aleksova J, Rodriguez A, McLachlan R, Kerr P, Milat F, Ebeling P Curr Osteoporos Rep. 2018; 16(6):674-692.

PMID: 30328552 DOI: 10.1007/s11914-018-0483-3.

Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.

Nagatoya K, Nishimoto K, Shibahara N, Takahashi T, Kanehara H, Ueno N Clin Exp Nephrol. 2014; 19(5):939-46.

PMID: 25504368 DOI: 10.1007/s10157-014-1065-z.

References

Jamal S, Chase C, Goh Y, Richardson R, Hawker G . Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis. 2002; 39(4):843-9. DOI: 10.1053/ajkd.2002.32006. View

Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F . Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003; 63(6):2269-74. DOI: 10.1046/j.1523-1755.2003.00005.x. View

Weisinger J, Gonzalez L, Alvarez H, Hernandez E, Carlini R, Capriles F . Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000; 58(1):331-5. DOI: 10.1046/j.1523-1755.2000.00170.x. View

Grey A, Stapleton J, Evans M, Reid I . Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin Endocrinol (Oxf). 1996; 44(6):697-702. DOI: 10.1046/j.1365-2265.1996.744565.x. View

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

Taal M, Cassidy M, Pearson D, Green D, Masud T . Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrol Dial Transplant. 1999; 14(8):1917-21. DOI: 10.1093/ndt/14.8.1917. View

Duschek E, Gooren L, Netelenbos C . Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas. 2005; 51(3):286-93. DOI: 10.1016/j.maturitas.2004.08.011. View

Riggs B . The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000; 106(10):1203-4. PMC: 381441. DOI: 10.1172/JCI11468. View

Alikhani M, Alikhani Z, Boyd C, MacLellan C, Raptis M, Liu R . Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2006; 40(2):345-53. PMC: 1913208. DOI: 10.1016/j.bone.2006.09.011. View

10.

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K . Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-23. DOI: 10.1016/j.cell.2007.07.025. View

11.

Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S . The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant. 1999; 14(5):1238-43. DOI: 10.1093/ndt/14.5.1238. View

12.

Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y . Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem. 2005; 51(12):2312-7. DOI: 10.1373/clinchem.2005.051524. View

13.

Ishani A, Blackwell T, Jamal S, Cummings S, Ensrud K . The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008; 19(7):1430-8. PMC: 2440292. DOI: 10.1681/ASN.2007050555. View

14.

Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E . Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002; 40(4):802-9. DOI: 10.1053/ajkd.2002.35692. View

15.

Kishimoto H . [CM-100]. Nihon Rinsho. 2004; 62 Suppl 2:305-8. View

16.

Park S, Jeong K, Moon J, Lee S, Ihm C, Rhee S . The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol. 2010; 14(3):239-43. DOI: 10.1007/s10157-010-0272-5. View

17.

Clarkson T . Raloxifene revisited. Fertil Steril. 2002; 77(3):445-7. DOI: 10.1016/s0015-0282(01)03224-1. View